Triple Negative Breast Cancer Clinical Trials in Chapel Hill, North Carolina

4 studies are recruiting for triple negative breast cancer in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

    This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
    Locations
    6 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07340541 on ClinicalTrials.gov

  2. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Locations
    372 in total
    Run by
    Gilead Sciences

    See if you can join NCT05633654 on ClinicalTrials.gov

  3. Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

    This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06347068 on ClinicalTrials.gov

  4. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Locations
    15 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.